NCT05062278View on ClinicalTrials.gov

Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 26, 2021

Primary Completion Date

July 1, 2025

Study Completion Date

December 1, 2025

Conditions
AMLHyperleukocytosis
Interventions
DRUG

Vinblastine

Single-dose of intravenous vinblastine at 6mg/m2 (maximum 10mg).

DRUG

Hydroxyurea capsules

Oral hydroxyurea at a dose of 50mg/kg/day until the administration of induction chemotherapy.

Trial Locations (1)

64460

RECRUITING

Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitario contra el Cancer, Monterrey

All Listed Sponsors
lead

Hospital Universitario Dr. Jose E. Gonzalez

OTHER